Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 708.16 Million EUR | 14.43% |
| 2022 | 559.34 Million EUR | 3.82% |
| 2021 | 596.31 Million EUR | 3.99% |
| 2020 | 566.83 Million EUR | 5.34% |
| 2019 | 544.36 Million EUR | 8.92% |
| 2018 | 501.5 Million EUR | 10.67% |
| 2017 | 456.66 Million EUR | 18.96% |
| 2016 | 377.71 Million EUR | 18.67% |
| 2015 | 321.75 Million EUR | 15.02% |
| 2014 | 277.29 Million EUR | 16.1% |
| 2013 | 244.49 Million EUR | 16.23% |
| 2012 | 191.86 Million EUR | 9.78% |
| 2011 | 187.74 Million EUR | 3.31% |
| 2010 | 181.73 Million EUR | -5.97% |
| 2009 | 193.26 Million EUR | 10.96% |
| 2008 | 174.17 Million EUR | 10.61% |
| 2007 | 157.46 Million EUR | 9.62% |
| 2006 | 143.64 Million EUR | 7.85% |
| 2005 | 133.18 Million EUR | 18.21% |
| 2004 | 115.18 Million EUR | 57.31% |
| 2003 | 71.62 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 231.76 Million EUR | 43.36% |
| 2024 Q2 | 189.96 Million EUR | -17.37% |
| 2023 Q4 | 160.25 Million EUR | 1.62% |
| 2023 Q2 | 179.25 Million EUR | -14.85% |
| 2023 Q1 | 210.52 Million EUR | 27.83% |
| 2023 Q3 | 157.69 Million EUR | -12.03% |
| 2023 FY | - EUR | 14.43% |
| 2022 Q3 | 162.01 Million EUR | 23.67% |
| 2022 FY | - EUR | 3.82% |
| 2022 Q1 | 161.42 Million EUR | 3.84% |
| 2022 Q2 | 130.99 Million EUR | -18.85% |
| 2022 Q4 | 164.68 Million EUR | 1.65% |
| 2021 Q1 | 146.27 Million EUR | 5.02% |
| 2021 Q4 | 155.45 Million EUR | 7.38% |
| 2021 Q3 | 144.77 Million EUR | -3.37% |
| 2021 FY | - EUR | 3.99% |
| 2021 Q2 | 149.81 Million EUR | 2.42% |
| 2020 Q4 | 139.28 Million EUR | 12.79% |
| 2020 FY | - EUR | 5.34% |
| 2020 Q1 | 170.87 Million EUR | 27.59% |
| 2020 Q2 | 139.8 Million EUR | -18.18% |
| 2020 Q3 | 123.48 Million EUR | -11.67% |
| 2019 Q3 | 129.41 Million EUR | -4.06% |
| 2019 FY | - EUR | 8.92% |
| 2019 Q4 | 133.91 Million EUR | 3.48% |
| 2019 Q1 | 144.26 Million EUR | 21.29% |
| 2019 Q2 | 134.89 Million EUR | -6.49% |
| 2018 FY | - EUR | 10.67% |
| 2018 Q4 | 118.94 Million EUR | 0.22% |
| 2018 Q3 | 118.67 Million EUR | -5.99% |
| 2018 Q2 | 126.23 Million EUR | -5.49% |
| 2018 Q1 | 133.57 Million EUR | 20.05% |
| 2017 Q1 | 118.57 Million EUR | 35.74% |
| 2017 Q2 | 107.8 Million EUR | -9.09% |
| 2017 Q3 | 116.98 Million EUR | 8.52% |
| 2017 FY | - EUR | 18.96% |
| 2017 Q4 | 111.27 Million EUR | -4.89% |
| 2016 Q4 | 87.35 Million EUR | -4.78% |
| 2016 Q1 | 99.02 Million EUR | 24.57% |
| 2016 Q2 | 88.66 Million EUR | -10.46% |
| 2016 Q3 | 91.74 Million EUR | 3.47% |
| 2016 FY | - EUR | 18.67% |
| 2015 Q4 | 79.49 Million EUR | 2.6% |
| 2015 Q1 | 82.49 Million EUR | 27.21% |
| 2015 Q2 | 79.8 Million EUR | -3.26% |
| 2015 Q3 | 77.47 Million EUR | -2.91% |
| 2015 FY | - EUR | 15.02% |
| 2014 FY | - EUR | 16.1% |
| 2014 Q2 | 70.63 Million EUR | -0.37% |
| 2014 Q4 | 64.84 Million EUR | -8.81% |
| 2014 Q3 | 71.1 Million EUR | 0.66% |
| 2014 Q1 | 70.9 Million EUR | 17.96% |
| 2013 Q4 | 60.1 Million EUR | -2.25% |
| 2013 Q2 | 55.3 Million EUR | -11.11% |
| 2013 Q1 | 62.21 Million EUR | 51.44% |
| 2013 FY | - EUR | 16.23% |
| 2013 Q3 | 61.48 Million EUR | 11.18% |
| 2012 Q1 | 54.02 Million EUR | 32.69% |
| 2012 Q2 | 48.23 Million EUR | -10.73% |
| 2012 Q3 | 48.52 Million EUR | 0.62% |
| 2012 Q4 | 41.08 Million EUR | -15.34% |
| 2012 FY | - EUR | 9.78% |
| 2011 Q4 | 40.71 Million EUR | -12.65% |
| 2011 FY | - EUR | 3.31% |
| 2011 Q1 | 50.45 Million EUR | 33.4% |
| 2011 Q2 | 49.96 Million EUR | -0.97% |
| 2011 Q3 | 46.61 Million EUR | -6.71% |
| 2010 Q4 | 37.81 Million EUR | -17.79% |
| 2010 Q2 | 48.2 Million EUR | -3.03% |
| 2010 FY | - EUR | -5.97% |
| 2010 Q3 | 46 Million EUR | -4.56% |
| 2010 Q1 | 49.71 Million EUR | 6.88% |
| 2009 FY | - EUR | 10.96% |
| 2009 Q1 | 48.21 Million EUR | 0.0% |
| 2009 Q2 | 49.31 Million EUR | 2.28% |
| 2009 Q4 | 46.51 Million EUR | -5.5% |
| 2009 Q3 | 49.21 Million EUR | -0.2% |
| 2008 FY | - EUR | 10.61% |
| 2007 FY | - EUR | 9.62% |
| 2006 FY | - EUR | 7.85% |
| 2005 FY | - EUR | 18.21% |
| 2004 FY | - EUR | 57.31% |
| 2003 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 94.671% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 96.353% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | 38.317% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 1883.556% |
| Novartis AG | 19.51 Billion USD | 96.372% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | -145.775% |